Non-patient related variables affecting levels of vascular endothelial growth factor in urine biospecimens

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 4, 2008, Pages 1250-1255

  Kirk, M J ^a   Hayward, R M ^a   Sproull, M ^a   Scott, T ^a   Smith, S ^a   Cooley Zgela, T ^a   Crouse, N S ^a   Citrin, D E ^a   Camphausen, K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Biospecimens; Tumour markers; Urine; VEGF

Indexed keywords

PROTEINASE INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABORATORY PERSONNEL; MALE; METABOLISM; PH; REPRODUCIBILITY; TIME; URINE;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; LABORATORY PERSONNEL; MALE; PROTEASE INHIBITORS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 49549099582     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00182.x     Document Type: Article

References (21)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971 285 : 1182 6.
2. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemc-itabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol. 2004 22 : 777 84.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinote-can, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 350 : 2335 42.
4. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 23 : 792 9.
5. Shih T, Lindley C. Bevacizumab: an angio-genesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006 28 : 1779 802.
6. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F. Bevacizumab in combination with fluo-rouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005 23 : 3502 8.
7. Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, Figg WD, Albert PS, Menard C, Camphausen K. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol. 2004 22 : 499 506.
8. Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D, Loening SA. Excretion of matrix metal-loproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology. 2001 57 : 675 9.
9. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metal-loproteinases in urine of cancer patients. Cancer Res. 1998 58 : 1395 9.
10. Poon RT, Fan ST, Wong J. Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches. Ann Surg. 2003 238 : 9 28.
11. Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci. 2001 38 : 225 62.
12. Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, Jinno K, Kotani Y. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer. 1998 34 : 2041 5.
13. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000 60 : 2898 905.
14. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001 19 : 1207 25.
15. McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, Grossman HB, Peng A, Taube SE, Waldman FM. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res. 2000 6 : 1854 64.
16. Landi MT, Caporaso N. Sample collection, processing and storage. IARC Sci Publ. 1997 142 : 223 36.
17. Pesce AJ, Michael JG. Artifacts and limitations of enzyme immunoassay. J Immunol Methods. 1992 150 : 111 9.
18. Yetkin G, Kuzucu C, Gucluer N. Distribution of bacteria isolated from urine cultures in Malatya University Hospital laboratory (letter). Mikrobiyol Bul. 2006 40 : 445 6.
19. Zhou H, Yuen PS, Pisitkun T, Gonzales PA, Yasuda H, Dear JW, Gross P, Knepper MA, Star RA. Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. Kidney Int. 2006 69 : 1471 6.
20. Klasen IS, Reichert LJ, de Kat Angelino CM, Wetzels JF. Quantitative determination of low and high molecular weight proteins in human urine: influence of temperature and storage time. Clin Chem. 1999 45 : 430 2.
21. Dejaegere A CL, Lafont V, De Genst E, Altschuh D. Variations in antigen-antibody association kinetics as a function of pH and salt concentration: a QSAR and molecular modeling study. Biochemistry. 2005 44 : 14409 18.